Genetic Factors Responsible for Alzheimer's Disease Identified

As opposed to the typical study design, which combines all such persons into a single group or focuses only on cognitively healthy persons, a new study identified several novel genetic associations within multiple subgroups.

A team of scientists led by those at Boston University School of Medicine (Boston, MA, USA) conducted genome-wide association studies for AD-related endophenotypes including hippocampal volume, logical memory scores, and CSF. They tested the association between AD-related brain MRI measures, logical memory test scores and CSF levels of two AD proteins amyloid-beta (Aβ42) and tau with several million genetic markers called single-nucleotide polymorphisms (SNPs) across the genome in a sample of 1,189 participants of the Alzheimer Disease Neuroimaging Initiative (ADNI) study. They then examined the biological significance of the top-ranked associated SNPs and genes using several datasets containing information about gene expression in parts of the brain most affected by AD.

The scientists found that two of the study-wide significant genes identified in the normal cognitive functioning group, Serine/Arginine Repetitive Matrix 4 (SRRM4) and Microtubule Associated Scaffold Protein 1(MTUS1), are involved in neuronal signaling, development and loss. Another gene identified in this group, Glutamate Ionotropic Receptor NMDA Type Subunit 2B (GRIN2B), encodes a subunit of a receptor that has roles in resilience of neurons and memory. They found consistent expression patterns of C14orf40 and MTUS1 in carriers with risk alleles of expression SNPs and in brains of AD patients, compared with in the noncarriers and in brains of controls.

Lindsay A. Farrer, PhD, Distinguished Professor of Genetics and principal investigator of the study, said, “Our findings provide important insight about biological mechanisms leading to Alzheimer disease, especially at stages of the disease before symptoms occur. The novel genes we identified may be potential targets for developing new treatments that might delay or even prevent onset of symptoms of this insidious disease.” The study was published on December 20, 2017, in the journal Alzheimer's & Dementia.

Related Links:
Boston University School of Medicine